|
rs2295080
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our meta-analysis of mTOR rs2295080 and cancer risk provided further evidence that mTOR SNPs might modulate cancer susceptibility.
|
25654238 |
2015 |
|
rs2295080
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Recently, a functional polymorphism (rs2295080 T>G) in the promoter of MTOR has been shown to influence its expression and confer susceptibility to cancer.
|
25776475 |
2015 |
|
rs2295080
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy.
|
24816861 |
2014 |
|
rs2295080
|
|
|
0.040 |
GeneticVariation |
BEFREE |
When estimated these two SNPs together, the combined genotypes with 2-4 risk alleles (rs2295080 T and rs7254617 A alleles) were associated with an increased risk of PCa compared with 0-1 risk alleles, which was more pronounced among subgroups of age >71 years, smokers, drinkers and no family history of cancer.
|
22815832 |
2012 |
|
rs2295079
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In humans, the rs2295080T-allele at the <i>mTOR</i> promoter locus has been associated with human cancer risk; however, the 63 bp spacing of another SNP rs2295079 has not been identified.
|
31467112 |
2019 |
|
rs1034528
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis found that rs1883965, rs1034528, and rs17036508 were correlated with increased cancer risk in the complete over-dominant model (rs1883965 GA versus GG/AA: fixed-effects OR=1.15, 95% CI 1.02-1.29; rs1034528 GC versus GG/CC: fixed-effects OR=1.30, 95% CI 1.13-1.48; rs17036508 TC versus CC/TT: fixed-effects OR=1.23, 95% CI 1.06-1.43).
|
27462867 |
2016 |
|
rs17036508
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis found that rs1883965, rs1034528, and rs17036508 were correlated with increased cancer risk in the complete over-dominant model (rs1883965 GA versus GG/AA: fixed-effects OR=1.15, 95% CI 1.02-1.29; rs1034528 GC versus GG/CC: fixed-effects OR=1.30, 95% CI 1.13-1.48; rs17036508 TC versus CC/TT: fixed-effects OR=1.23, 95% CI 1.06-1.43).
|
27462867 |
2016 |
|
rs1883965
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis found that rs1883965, rs1034528, and rs17036508 were correlated with increased cancer risk in the complete over-dominant model (rs1883965 GA versus GG/AA: fixed-effects OR=1.15, 95% CI 1.02-1.29; rs1034528 GC versus GG/CC: fixed-effects OR=1.30, 95% CI 1.13-1.48; rs17036508 TC versus CC/TT: fixed-effects OR=1.23, 95% CI 1.06-1.43).
|
27462867 |
2016 |
|
rs11121704
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our meta-analysis results showed that the wild genotype TT of rs2295080 polymorphism was associated with increased cancer risk under dominant model (OR = 1.24, 95%CI: 1.12-1.36, p<0.0005) in Chinese but not with clinical outcome parameters, while the TT genotype of rs11121704 was associated with poor clinical outcome parameters (OR = 1.53, 95%CI: 1.01-2.32, p = 0.044), such as death, metastasis and resistance to chemotherapy.
|
24816861 |
2014 |
|
rs2536
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, rs2536 may not influence cancer susceptibility.
|
24816861 |
2014 |